Mismatch Deoxyribonucleic acid Repair

88 DNA MMR deficiency is linked to the development of multiple types of malignancy secondary to the persistence of mismatched mutations in regions of repetitive Dna (microsatellites) leading to microsatellite instability (MSI) and production of truncated protein products.

From: Stiehm's Immune Deficiencies (2nd Edition) , 2020

Class switch recombination defects

A. Durandy , S. Kracker , in Stiehm's Immune Deficiencies (2d Edition), 2022

Disease machinery

PMS2 is an 862 amino-acrid nuclear protein. Information technology belongs to the DNA MMR complex, which has two main components: the MutS homolog (MSH1–6) and the MutL homolog (PMS2/MLH1/PMS1). Dna repair is initiated by MutSα (MSH2-MSH6), which binds to DNA mismatches and recruits MutLα (PMS2/MLH1). Assembly of the MutLα-MutSα complex on the mismatch is enough to activate the endonuclease action of PMS2, which introduces Dna breaks near the mismatch and thus generates new entry points so that EXO1 exonuclease can degrade the strand containing the mismatch. Defects in this pathway impair MMR and thus cause susceptibility to various types of malignancies.

The MMR enzymes (and PMS2 especially) are also involved in the repair of Assist-induced U:G mismatches that are non processed by UNG. The fact that a very severe CSR defect occurs in UNG-deficient patients 105 indicates that the MMR complex is non an efficient alternative for BER in CSR but is likely situated downstream of UNG in the same pathway. In the absence of PMS2, the observation of a low DSB frequency in S regions (and thus depression CSR efficacy) highlights the role of PMS2'southward endonuclease activeness in this process. Nevertheless, PMS2 is non essential for SHM considering the latter does not require the generation of DSBs. 26

As in humans, PMS2-deficient mice appear prone to tumors (such as sarcoma and lymphoma). 111 Male mice defective PMS2 are infertile and produce only abnormal spermatozoa. 111 The CSR-D is less pronounced than in humans (with only a fifty% drop in switched isotype product, relative to the wild type) 112 and is associated (as in humans) with defective Assistance-induced DNA lesion processing and DSB generation. 26 , 113 , 114 Interestingly, PMS2 KO mice accept a CSR-D, 115 showing that PMS2'due south endonuclease activity has a specific role in CSR just non in SHM.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780128167687000193

DNA Replication, Repair, and Mutagenesis

N.5. Bhagavan , Chung-Eun Ha , in Essentials of Medical Biochemistry (Second Edition), 2022

Excision Repairs

Deoxyribonucleic acid impairment that has happened to ane strand of DNA tin can be accurately corrected past excision Deoxyribonucleic acid repair systems. When the other, intact, Dna strand is used every bit template, the damaged sites are excised and replaced with new Deoxyribonucleic acid by specific enzymes. All organisms employ at least three types of excision repair systems: mismatch repair, base excision repair, and nucleotide excision repair.

Mismatch DNA repair systems right base mismatches introduced during Dna replication despite the polymerase's proofreading power. In bacteria, mismatches of bases in newly synthesized DNA strands are recognized by a repair system, since parental template strands of Deoxyribonucleic acid are methylated. Newly synthesized Deoxyribonucleic acid strands are not methylated immediately later on DNA synthesis, and therefore, a mismatched base on the unmethylated DNA strand is changed to the base complementary to the base of the methylated strand. 3 cardinal components are required for mismatch repair systems in E. coli: MutS, MutL, and MutH proteins. If a T–G mismatch was introduced in Dna, MutS protein scans the Deoxyribonucleic acid sequence and binds to the mismatched base. Then MutH protein, which is an endonuclease, recognizes the methylated Dna sequence of GATC on the parental strand, and MutL links MutH and MutS. The linked MutH protein nicks the opposite strand of the methylated A base on the parental strand. Then, the helicase, UvrD, unwinds DNA from the nick and proceeds past the mismatched nucleotide. Exonucleases cutting abroad the nicked GATC sequence, and unmarried-strand binding proteins stabilize the resulting single strand. The excised Dna region is resynthesized by DNA polymerase III, and Deoxyribonucleic acid ligase seals the nick to form double-stranded Dna. The stop result of the mismatch repair system is a T–G mismatch correction respective to the methylated parental strand sequence (Effigy 22.xi). In eukaryotes, a Deoxyribonucleic acid single base mismatch is recognized by MSH2-MSH6 heterodimer proteins, and MLH1, PMS2, and EXO1 proteins serve the function of MutL in prokaryotes. However, the counterpart of prokaryotic MutH protein has not been identified in eukaryotes.

Figure 22.11. Prokaryotic mismatch repair. In mismatch repair, a pair of non-hydrogen-bonded bases (east.g., M:T) within a helix is recognized by MutS, and a polynucleotide segment of the daughter strand is excised, thereby removing one member of the unmatched pair. The resulting gap is filled in by pol III, and so the terminal seal is made by Dna ligase.

Base excision repair (BER) systems handle a wide diverseness of individual base damage acquired by oxidation, alkylation, and deamination. Three major steps are involved in BER. First, the damaged base is recognized and removed by an advisable Dna North-glycosylase. The DNA N-glycosylases remove the damaged bases out of the Deoxyribonucleic acid strand by cutting glycosidic bonds betwixt deoxyribose sugar and heterocyclic bases, creating an apurinic or apyrimidinic (AP) site. Next, another enzyme chosen AP endonuclease creates a nick past cleaving the sugar–phosphate backbone at the AP site, creating a iii′-OH terminus adjacent to the AP site. The gap at the AP site is and so filled by the action of Dna polymerase and DNA ligase (Figure 22.12).

Effigy 22.12. Scheme for base excision repair (BER). BER repairs incorrect bases (e.grand., U) and damaged bases (due east.yard., deaminated C, methylated A).

In addition to BER, all organisms adopt nucleotide excision repair (NER) systems to preserve genomic stability and overcome the consequences of Dna damaging agents. The NER system is effective in removing bulky Deoxyribonucleic acid damage caused by UV calorie-free, oxidative chemicals, reactive oxygen species, cross-linking agents, and intercalating antineoplastic drugs. NER involves several steps: damage recognition, removal of damaged bases, and new DNA synthesis at the site. The E. coli NER organization requires four proteins: UvrA, B, C, and D. UvrA dimer recognizes Dna damage and binds to the damaged site with UvrB. Then the UvrA dimer is replaced by UvrC to form a UvrBC complex. The UvrBC complex cleaves a 5th phosphodiester bond at the 3′ side and an 8th phosphodiester bond at the 5′ side of the damaged Dna site. Then UvrD (helicase) unwinds the DNA to release the damaged DNA strand and expose the single-stranded region. Dna polymerase I fills the excised regions, and Dna ligase seals the nick, completing the repair procedure (Figure 22.13). NER in eukaryotes is similar to the prokaryotic system. However, the eukaryotic NER system is much more than complicated and involves more proteins. For example, the man NER system includes 17 proteins, which collaborate to repair Dna damage. The human being disease xeroderma pigmentosum (XP) is caused by defects in the NER system. Investigations of XP patients have led scientists to identify the NER components: XPA to XPG. In eukaryotes, XPA protein binds to the damaged DNA site. XPB and XPD proteins are helicases to unwind the damaged DNA duplex. XPG cleaves the 3′ side of the damaged strand, and the XPF/ERCC1 circuitous cleaves the 5′ side of the damaged strand, generating a unmarried-stranded region of 24–32 bases covering the damaged site. The single-stranded portion is filled with correct base sequences by Deoxyribonucleic acid polymerase δ/ε along with regular DNA replication complexes.

Figure 22.thirteen. Nucleotide excision repair of a thymine dimer.

Read full chapter

URL:

https://www.sciencedirect.com/scientific discipline/article/pii/B9780124166875000221

Methylation and other Modifications of Nucleic Acids and Proteins☆

J.-R. Zhang , ... H. Deng , in Encyclopedia of Microbiology (4th Edition), 2022

Dam-Directed Mismatch Repair

The concentration of Dam in the cell is regulated to exist less than that needed for rapid methylation of all available sites in the DNA. This results in nether-methylation of the newly synthesized DNA concatenation relative to the parental strand, which is fully methylated. This difference in methylation land is exploited by a DNA repair system (Dam- or methyl-directed Dna mismatch repair) that removes errors generated by the replication mechanism from the newly synthesized strand (Figure 4). If the replication mechanism makes a mistake, information technology will be present in the newly synthesized (unmethylated) strand as a base mismatch and be recognized by the MutS protein. After specific recognition, MutL is recruited followed by MutH that activates its latent endonuclease activeness to nick the unmethylated strand (Figure 4). The UvrD helicase enters at the nick and unwinds the Dna making the nicked strand bachelor for exonuclease digestion. The gap and so formed is filled by DNA polymerase 3, the replicative enzyme, followed by ligation by Deoxyribonucleic acid ligase and methylation of the GATC sites by Dam methyltransferase. Annotation that MutH tin cut only if the substrate Dna is hemimethylated; fully methylated is not a substrate for MutH endonuclease activeness, thereby targeting repair to the region simply behind the replication fork. Inactivation of this mismatch repair pathway increases the spontaneous mutation frequency 100- to 1000-fold relative to the wild-blazon strain indicating its importance in proofreading newly replicated Dna. In dam bacteria, discrimination betwixt the new and old strands is lost and, therefore, one-half the time it is expected that mismatch repair introduces mutations into the Deoxyribonucleic acid resulting from replication errors. This is reflected in the mutator phenotype associated with the dam mutant.

Figure 4. Dam-directed mismatch repair in E. coli. The top of the figure shows Dna immediately behind the replication fork in which the 'old' meridian strand is methylated and the 'new' strand is not; it also contains a base mismatch (carat) created every bit a replication error. The mismatch is recognized and bound by MutS followed by recruitment of MutL and MutH to form a ternary complex. The formation of this circuitous is thought to involve Dna looping to bring the mismatch and a GATC sequence in close proximity but the details are unclear. In the ternary circuitous, the latent nuclease activity of MutH is activated, which cleaves the new unmethylated strand 5′ to the GATC sequence. The nick created by MutH serves every bit an entry site for the UvrD helicase, which unwinds the DNA exposing single-stranded DNA which is digested by 1 or more of the following exonucleases: RecJ, ExoVII, ExoX, or ExoI. The exonuclease(due south) used depends on the relative orientation of the mismatch to the GATC sequence; in the figure, the direction of UvrD unwinding is 5′ to three′ and so either ExoVII or RecJ or both are needed. If the mismatch was to the 'right' of the GATC sequence, UvrD would unwind in the 3′ to 5′ direction and Exo10 and/or ExoI would assimilate the single-stranded Dna. The gap created by nuclease digestion is filled in by DNA polymerase III. The resulting nick is closed past Deoxyribonucleic acid ligase and eventual Dam methylation in the newly synthesized strand precludes any further repair.

 Reproduced from Marinus MG (2005) Dr. Jekyll and Mr. Hyde: How the MutSLH repair organization kills the cell. In: Higgins NP (ed.) The Bacterial Chromosome, pp. 413–440. Washington, DC, with permission of the American Society for Microbiology Press.

Read full affiliate

URL:

https://www.sciencedirect.com/science/article/pii/B978012801238302448X

The Virus equally a Concept – Fundamentals of Virology

Chris M. Rands , Harald Brüssow , in Encyclopedia of Virology (Fourth Edition), 2022

Coevolution: In the Patient

Coevolution between phages and leaner is not only seen from comparative genomics, highly dynamic phage-bacterium relationship changes were likewise documented over much shorter time periods. In microcosm laboratory experiments Pseudomonas fluorescens evolving under phage pressure showed an increased mutation rate and evolved greater genome broad divergence specially over the LPS cistron cluster, the receptor of many phages. The evolved bacteria showed as well greater fettle when tested in the absence of phages against the original strain. In Southward. pyogenes a phage integrates into the Deoxyribonucleic acid mismatch repair genes mutS-mutL, increasing the mutation charge per unit of the bacterium 200-fold. The cell uses this phage integration as a molecular switch, since the prophage is excised at low prison cell density restoring normal mutation rates. Short term phage-induced evolution was also seen in cholera patients that showed, in addition to V. cholerae, likewise a vibriophage in the stool. Bacterial colonies isolated from individual cholera patients were practically all resistant to this vibriophage and isogenic to the infecting strain except for mutations in an outer membrane porin and a ToxR signaling poly peptide, which activates virulence gene expression under host environmental stimuli. These ToxR mutants were adulterate in mouse infection model. Patently, V. cholerae evolves under phage pressure to lesser virulence in the later form of human cholera infection. Notably, evolution of the cholera pathogenicity was as well described over the course of an individual cholera outbreak and also linked to an increase in phage prevalence. The development of pregnant environmental phage titer might actually end a cholera season.

Other instructive examples are provided by comparison S. aureus colonizing the nose of healthy subjects or the lungs of cystic fibrosis patients. The frequency of genome alterations was significantly higher in the patients than in the controls. In nearly half of the patients, the genome alterations were linked to prophage mobilization, mostly by integration into a unmarried bacterial gene. Phage translocation in the patients leads to a splitting of the bacterial population into various subtypes differing in virulence gene composition, each of which might have different selective advantages for the pathogen in the patient. Phage mobilization seems to be induced by the frequent antibiotic treatment in the patients.

Read total affiliate

URL:

https://www.sciencedirect.com/science/commodity/pii/B9780128096338209710

Oncolytic viruses in immunotherapy

Ilse Hernandez-Aguirre , Kevin A. Cassady , in Cancer Immunology and Immunotherapy, 2022

viii.3 Herpes simplex virus (HSV-ane and HSV-2)

HSV is an enveloped double-stranded DNA virus in the Herpesviridae family unit with a well characterized genome and produces both lytic and latent infection in the host. HSV was one of the starting time viruses developed for OV therapy and initial efforts involved thymidine kinase (TK) cistron deletional mutants (ΔTK) [277], Martuza et al. showed that the (ΔTK) mutant was attenuated and in mouse pre-clinical studies could be safely injected in the CNS to suppress glioma tumor growth and prolonged survival. This strategic gene deletion however also eliminated virus antiviral therapy susceptibility [278]. Since then, oHSV containing other viral factor modifications to ameliorate selective replication accept been used involving attenuating mutations in several genetic locations as well every bit insertion of dissimilar immunomodulatory genes to modulate the virus induced immune action. Advantages of HSV as oncolytic vectors are: (i) its well characterized genome, (2) well-established methods for genetic modification of the virus, (three) a large packaging chapters that permits numerous transgene inserts to arm the virus, (4) decades of clinical use and prophylactic experience in patients even when directly injected into the CNS and antiviral therapy that is well tolerated and has a loftier therapeutic index. The virus also elicits a robust immune-mediated and inflammatory response involving intrinsic, innate, adaptive, and humoral response changes. It is not surprising that HSV-1 was the first FDA approved oncolytic virus for therapy. T-VEC was approved in 2022 after showing improved efficacy in patients with melanoma than those treated with GM-CSF lone [279].

Many of the oHSVs developed to date and advancing to clinical trial (including TVEC) incorporate deletional mutations that eliminate the chief neurovirulence gene of the virus or RL1. HSV encodes 2 copies of the γane34.five gene and information technology suppresses several of the IFN dependent host antiviral response pathways (PKR-mediated translational arrest, autophagy, early on IRF3-mediated signaling and IFN b1 induction) triggered by viral infection and gene expression [19,22,23,280]. Deletion of this gene restricts efficient viral replication in cells with intact type I IFN signaling pathways and dsRNA translational abort response and attenuates the virus (WT LD50 40-100pfu versus Δγ134.5   >   i   ×   10ee7). Clinical evolution of Δγ134.5 recombinants for brain tumor therapy occurred simultaneously in the United States and United kingdom of great britain and northern ireland. The virus developed in Great U.k. (HSV1716) contained Δγ134.five mutations alone. The oHSV developed early in the U.s. for CNS tumor treatment (G207) was conservatively designed for rubber and contained an boosted UL39 ribonucleotide reductase gene mutation to further benumb it and restrict viral replication to cells with a high proliferation index (cancerous cells). These mutations restrict viral replication and factor expression in some tumors. To overcome this replication restriction, investigators have used the Δγ134.5 or G207 courage viruses and incorporated other mutations or gene inserts (alpha Us11, HCMV IRS1), or incorporated conditional factor expression using tumor-specific promoters (e.g., Nestin promoter) to enhance viral replication in tumor cells [41,107,111,112,277,281,282]. Another virus used early on clinically (NV1020) for peripheral tumors besides has deletion in ICP0 and ICP4 (genes important for regulating viral transcription and too as cell bike shifts in the infected cell) and a single γ134.v re-create [283]. Other attenuating mutations have been used in oHSVs. For example, a virus adult in Japan contains UFifty53 mutation that is benumb through a less characterized machinery. In improver, investigators accept developed HSV2 based U5039 oncolytics. HSV has also been modified for cancer prison cell receptor retargeting Investigators have incorporated unmarried chain antibiotic recognition domains against HER2 to HSV to confer selective HER2 receptor tropism [284]. Investigators also substituted the viral glycoprotein domain with the HER2 targeting domain to create a chimeric glycoprotein capable of binding and fusion with tropism for HER2 cells to farther heighten selectivity, efficacy, and safety of this virus for breast cancer. Moreover, others accept adult HSVs that are field of study to miRNA control such that in nonmalignant cells they restrict viral gene expression that is relieved in cancerous cells where these miRNAs are absent-minded.

HSV elicits a brisk and agile immune prison cell response involving both intrinsic antiviral cytokine chemokine and IFN production too as humoral, innate and adaptive T-cell responses. To further enhance or augment this immune activeness, different cytokines have been added every bit transgenes in some instances. As mentioned previously T-VEC contains the GM-CSF gene to increase antitumor immunity, in the form of increased tumor-specific CD8 T-cells and a decrease in CD4 FOXP3 regulatory T-cells and CD8 FOXP3 T-cells.

viii.3.1 HSV1716

HSV1716 is a Δγone34.5 virus from the lab adapted and more than neurovirulent HSV strain 17 that was developed by Moira Chocolate-brown in the Britain. It has successfully completed early-stage safety studies where information technology was directly injected into CNS tumors from patients with recurrent malignant gliomas. The virus has also been safely administered (direct intra-tumoral injection) to pediatric patients with sarcomas. The avirulent virus was remarkably effective in these early phase studies in patients with recurrent tumors. 4 of the 9 patients survived 14–24   months mail service treatment (up to 10ee5 PFU). A stage Ib study followed this initial report and again the 12 treated patients had resection of their tumor iv-9d later. HSV 1716 was condom and replicated in both HSV immune and HSV seronegative patients. Patients were so injected with HSV 1716 in the tumor margins following surgical resection 3 of the 12 treated patients had long-term survival of 15–22   months. In pediatric sarcoma studies, HSV 1716 was as rubber as in the adult studies; however, the clinical benefits were not as pronounced in pediatric sarcomas [285]. Virus replication was detectable (PCR positive in blood stream) and tardily inflammatory radiographic changes suggestive of an immune-mediated component were detected in some patients [285] The clinical benefits were not equally pronounced except in one patient with a documented Dna mismatch repair mutation [285]. Taken together these results suggest that immune action and antigenic load may be an important factor in durable responses following oHSV therapy or that some cancers may be less acquiescent to the allowed-mediated antitumor effects of virotherapy.

8.iii.2 Talimogene Laherparepec (T-VEC, IMLYGIC)

T-VEC was a breakthrough oncolytic virus, being the commencement OV to be FDA approved for treatment. T-VEC is an attenuated HSV-ane oncolytic virus with double deletion of ICP34.5 and ICP47, as well as the insertion of GM-CSF gene for expression [53]. The ICP47 mutation served 2 functions that enhance its therapeutic potential. The mutation enhances MHC I antigen presentation in infected cells (eliminating the virus encoded TAP inhibitor) and eliminates the UDue south11 g2 promoter leading to before expression of the dsRNA binding poly peptide USouth11 and PKR evasion in infected cells. Phase I studies were conducted with the purpose of determining the safety contour of the virus, too as identifying a dosing schedule for later studies [286]. 30 patients were enrolled with breast, head and cervix, gastrointestinal cancers and malignant melanoma that previously failed therapy. This was a dual accomplice study and included a dose finding cohort to first identify the maximum tolerated dose of TVEC. Afterward establishing the MTD a 2nd cohort received multiple doses of the virus initially at the MTD and then with increased doses after patients seroconverted. The virus was well tolerated in the multi-dose accomplice. The goal was to arm-twist an antitumor upshot and although there were no complete or partial responses, TVEC produced stable disease. Based upon the promising early stage results, TVEC was avant-garde to a single arm phase II study involving 50 patients with unresectable metastatic melanoma [287]. Patients had a 26% response rate with regression of both injected and noninjected lesions, including visceral, in those patients who responded to the therapy, providing prove of systemic effectiveness. Information technology besides paved the way for a U.s.a. Nutrient and Drug Administration (FDA) phase Iii clinical trial to take place. In their phase 3 clinical trial, they tested TVEC and GM-CSF in 436 patients with unresectable melanoma in a randomized controlled trial [279]. In the Phase Three trial TVEC improved both the durable response rate and the overall response rate over GM-CSF therapy. Efficacy was most pronounced in patients with phase IIIB, IIIC, and IVM1a melanoma and in patients with treatment-naïve disease. With TVEC being well tolerated, it was the first oncolytic immunotherapy to demonstrate therapeutic effect against melanoma in a stage III clinical trial, leading to its FDA approving later in 2022. Follow upward clinical studies are examining TVEC in combination with other immunotherapeutics (checkpoint therapy) every bit a way to expand the immune-mediated activity of OV therapy.

viii.3.3 G207 (and G47delta)

G207 is another HSV-based virotherapy, this one with deletions of the ICP34.5 genes and insertion of the lacZ to disable the UL39 gene [39, 41]. Afterward demonstrating feasibility of this therapy in animal models, a stage I clinical trial was conducted for the handling of malignant glial tumors in 21 human subjects, and no toxicity or a serious adverse event observed most importantly, no patient adult HSV encephalitis and clinical response in select patients, and they establish presence of viral DNA and some viral gene expression in select patients. G207 (and HSV1716) provided valuable information and a genetic platform for further cistron modifications and improvements. It recently completed a phase I trial in pediatric patients with supratentorial (medulloblastoma) and improved result. Another phase Ib clinical trial took place to ensure the safety of two inoculations of G207, before and subsequently tumor resection, and appeared safe for multiple doses [44]. Some other stage I clinical trial was done to test for safety of G207 in combination with radiation for recurrent glioblastoma, with a single dose of virus given 24   h earlier a 5Gy radiations dose [288]. While G207 is a 2nd-generation virus, G47delta is a tertiary generation virus derived from G207 that incorporates an alpha47 and US11 promoter deletion similar to that engineered in TVEC [282]. This mutation as described previously enhances MHC I antigen expression in infected cells and improves protein translation in the infected cell by shifting USxi expression earlier in infection which enables the virus to prevent PKR-mediated translational abort in the infected cell [282]. It has been tested in phase I and Two clinical trials in Nihon against glioblastoma (JPRN-UMIN000002661), prostate cancer, and olfactory neuroblastoma, with promising results [289].

8.iii.four NV1020

NV1020 was derived from an HSV recombinant R7020 and contains a 15   kb deletional mutation at the extending into the U50 and USouth  junction and fixes the virus in an isomeric genetic form. The large genetic deletion eliminates one copy of the diploid α0, αfour, and γane 34.5  genes (encoding the ICP0, ICP4, and ICP34.five proteins), respectively, and the U L 56 cistron, the poly peptide production of which has not been fully characterized but is idea to contribute to HSV neuroinvasiveness [283,290]. NV1020 was administered in a phase I study to patients with refractory metastatic colorectal cancer to the liver who had already received fractional hepatectomy and adjuvant chemotherapy handling. Patients were enrolled in the 3   ×   iii dose escalation study (3   ×   x6–ane   ×   xeight PFU) and were administer the virus past hepatic artery infusion. No serious agin events or dose limiting complications occurred and a maximal tolerated dose was not determined. Ix of the 12 treated patients had stable or reduced tumor burden and the median survival for the grouping was 25   months [291].

Several other next generation oncolytic HSVs are currently in phase I clinical trial for patients with recurrent malignant gliomas and GBM. These include a Δγ134.five hIL12 expressing oHSV M032 (NCT02062827), a chimeric HSV Δγ134.five HCMV IRS1 expressing oHSV capable of improved protein translation and replication (NCT03657576) and an elegantly designed oHSV (rQNestin34.5v.two) that resembles a conditionally expressing G207 vector. It contains the RR mutation (ΔUL39) only places the γi34.v IFN evasion neurovirulence gene under nestin dependent promoter control to raise conditional viral translation and replication activity in glioma cells rather than deleting the cistron equally occurs in G207 (NCT03152318). HSV-1 rRp450 is a U5039 deletional mutant derived from KOS strain that is also in early-stage study in patients with primary liver cancer or liver metastases administered by hepatic arterial infusion every 1–two   weeks in upward to 4 full doses (NCT01071941). Melanoma studies using ONCR-177 in combination with Pembrolizumab PD-1 blockade are also underway (NCT04348916) in patients with melanoma, squamous cell carcinoma of head and cervix, breast cancer or other advanced solid tumors. ONCR-177 is a mIR-regulated oHSV that permits provisional Immediate Early on and γi34.5 cistron expression in cancerous cells (that practise not express the mIRNA). The oHSV expresses 5 transgenes (IL-12, CCL4, the extracellular domain of FLT3L and checkpoint inhibitors targeting PD-1 and CTLA-four) and includes mutations that limit axonal retrograde send equally an added safety measure and to prevent the virus from establishing latency. In Nihon, HF10, spontaneously mutated HSV variant with natural oncolytic activity and an advantageous safety profile has avant-garde from Phase I to 2 study. Several clinical trials involving HF10 alone, HF10 with chemotherapy, or HF10 with chemotherapy or HF10 with ipilimumab or Nivolumab combinations are being performed in patients with melanoma, solid tumors, or with metastatic pancreatic cancer (JapicCTI-173,591, NCT03153085), (NCT02272855), (NCT03259425), (JapicCTI-173,671, NCT03252808).

Read total chapter

URL:

https://www.sciencedirect.com/scientific discipline/article/pii/B9780128233979000120

Mismatch repair in Gram-positive bacteria

Justin S. Lenhart , ... Lyle A. Simmons , in Inquiry in Microbiology, 2022

Abstruse

DNA mismatch repair (MMR) is responsible for correcting errors formed during DNA replication. DNA polymerase errors include base of operations mismatches and extra helical nucleotides referred to equally insertion and deletion loops. In bacteria, MMR increases the fidelity of the chromosomal Deoxyribonucleic acid replication pathway approximately 100-fold. MMR defects in leaner reduce replication fidelity and have the potential to affect fitness. In mammals, MMR defects are characterized past an increase in mutation rate and past microsatellite instability. In this review, nosotros discuss current advances in agreement how MMR functions in bacteria lacking the MutH and Dam methylase-dependent MMR pathway.

Read full commodity

URL:

https://www.sciencedirect.com/science/article/pii/S0923250815001461